T-cell Receptor-engineered T-cells

Phase 1Biologic

T-cell Receptor-engineered T-cells is one of 14 biologic programs targeting Metastatic Malignant Solid Neoplasm. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Malignant Solid NeoplasmRecruiting

Metastatic Malignant Solid NeoplasmPhase 1

Recruiting

Competition

Competitive Landscape

14 competitors in Metastatic Malignant Solid Neoplasm

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

1 2

Tasigna

AAzurity Pharmaceuticals

Phase 2

1 3

Fludara

Sanofi

Phase 1

1 4

Keytruda

Merck & Co.

Phase 1

1 5

Herceptin

OOrganon and Co

Phase 1

2 6

Cytoxan

BBaxter Healthcare Corporation

Phase 1

1 7

Treanda

AAzurity Pharmaceuticals

Phase 1

1 8

Trastuzumab Deruxtecan

AstraZeneca

Phase 1

2 9

Hycamtin

MMeitheal

Preclinical

1 10

Pidnarulex

NNational Cancer Institute (NCI)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Metastatic Malignant Solid Neoplasm

NCT06043713

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Withdrawn·FFred Hutchinson Cancer Center·Phase 1·NCT06094842

Metastatic Malignant Solid Neoplasm1 trial

Phase I Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors in Participants With Metastatic Solid Tumors With KRAS G12V Mutations

Recruiting·FFred Hutchinson Cancer Center·Phase 1·NCT06043713·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for T-cell Receptor-engineered T-cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — T-cell Receptor-engineered T-cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for T-cell Receptor-engineered T-cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fred Hutchinson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: FFred Hutchinson Cancer Center

T-cell Receptor-engineered T-cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Prostate Cancer1 trial

Metastatic Malignant Solid Neoplasm1 trial

References

Drug Info

Quick Facts

Related News